Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects.
Investment fund Pharma Connect Capital (PCC), established on 10 October 2017, invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects. In doing so, PCC contributes to closing the innovation and financing gap that emerged in recent years now that the pharmaceutical industry is delegating more and more tasks.
PCC is professionally managed by Jan Hendriks (CEO Innocore Pharmaceuticals, former board member of Ing. G.J. Smid fund and former CEO of Pharma-Bio Research). This experienced entrepreneur comes from the dynamic environment of Groningen, where a wide variety of Life Sciences companies together form a solid and unique cluster of activities. Together with the University Medical Center Groningen and the University of Groningen, they form the lifeblood of this industry in the region. Hendriks provides PCC with a large network of national and international contacts. The fund works closely together with the Pharma Portal. Groningen shows its ambition with the Pharma Connect Capital fund.
These cookies make sure the website functions properly. These cookies also provide us to anonymously monitor website statistics. Because these cookies are essential for the website, you can not disable them without compromising the functionality of the website.
These cookies collect data that we use to understand how our website is used and perceived. These cookies also help us to optimize the website for the best user experience.
These cookies allow ad-networks to monitor your online behaviour so they can display relevant ads based on your interest and online behaviour. These cookies also prevent the same ads from being displayed over and over.
